Bicara Therapeutics BCAX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's deferred tax assets and other non-current assets?
- Bicara Therapeutics (BCAX) reported deferred tax assets and other non-current assets of $6.91M in Q1 2026.
- How has Bicara Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Bicara Therapeutics's deferred tax assets and other non-current assets increased by 4.1% year-over-year, from $6.64M to $6.91M.
- What is the long-term trend for Bicara Therapeutics's deferred tax assets and other non-current assets?
- Over 2 years (2023 to 2025), Bicara Therapeutics's deferred tax assets and other non-current assets has grown at a 81.7% compound annual growth rate (CAGR), from $2.09M to $6.91M.